SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift Laboratories informs about interest payment

22 Jun 2023 Evaluate
Pursuant to Regulation 57 (4) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Ind-Swift Laboratories has informed about details of interest obligations in respect of the Non-Convertible Debentures of the Company, which are due to be paid during the quarter ending 30th September, 2023-Q2 F/Y 2023-24.

The above information is a part of company’s filings submitted to BSE.

Ind-Swift Lab. Share Price

135.80 -2.05 (-1.49%)
24-Apr-2026 11:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1621.00
Dr. Reddys Lab 1325.15
Cipla 1287.00
Zydus Lifesciences 931.95
Lupin 2285.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×